Related Experiment Video

Updated: Oct 10, 2025

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice
04:10

Noninvasive Intratracheal Lipopolysaccharide Instillation in Mice

Published on: March 31, 2023

5.4K

Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial

Thorsten M Leucker1, William O Osburn1, Paula Reventun1

  • 1Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

JACC. Basic to Translational Science
|December 14, 2021
PubMed

Insights

P-selectin inhibition with crizanlizumab reduced inflammation markers in COVID-19 patients. While it affected thrombosis biomarkers, clinical outcomes showed no significant difference, suggesting potential thrombolysis effects.

Area of Science:

  • Cardiovascular Medicine
  • Infectious Diseases
  • Hematology

Background:

  • COVID-19 is associated with vascular inflammation and thrombosis.
  • Elevated P-selectin levels are observed, indicating endothelial cell activation and inflammation.

Purpose of the Study:

  • To evaluate the impact of P-selectin inhibition on thrombosis and inflammation biomarkers in COVID-19 patients.
  • To assess the safety and tolerability of crizanlizumab in this patient population.

Main Methods:

  • A double-blind, randomized trial involving hospitalized patients with moderate COVID-19.
  • Participants received either placebo or crizanlizumab, a P-selectin inhibitor.
  • Biomarkers of inflammation and thrombosis were measured.

Main Results:

  • Crizanlizumab significantly reduced P-selectin levels by 89%.
  • D-dimer levels increased by 77% with crizanlizumab, while prothrombin fragment levels decreased.
  • No significant differences in clinical endpoints were observed between the crizanlizumab and placebo groups.

Conclusions:

  • P-selectin inhibition with crizanlizumab effectively reduced P-selectin levels in COVID-19 patients.
  • The drug demonstrated potential effects on thrombolysis biomarkers.
  • Crizanlizumab was well-tolerated and showed no significant impact on clinical outcomes in this study.

Keywords:
CRP, C-reactive proteinIL, interleukinTAT, thrombin antithrombinTNF, tumor necrosis factorVTE, venous thromboembolismVWF, von Willebrand factorcoronaviruscrizanlizumabendothelialexocytosisinflammationthrombosis

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.4K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
284
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
256
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
236